UAE drug-control push puts 3 pharmacy risks back on clinic agendas

UAE Public Prosecution used a 28 September 2026 panel at the 15th United Nations Congress on Crime Prevention and Criminal Justice in Abu Dhabi to press an integrated drug-control model that links prevention, treatment and law enforcement.

The highest-stakes readers are COOs, pharmacy directors and insurers. The announcement does not create a new pharmacy rule by itself. It signals tighter coordination between prosecutors, the National Anti-Narcotics Authority, health regulators and treatment providers, which matters for any clinic prescribing or dispensing narcotic, controlled or semi-controlled medicines in Dubai, Abu Dhabi and the northern emirates.

What changed in Abu Dhabi

Emirates News Agency reported that Dr. Saeed Al Ahbabi, a prosecutor at the Federal Drug Prosecution, spoke during a panel organised by the National Anti-Narcotics Authority on the sidelines of the UN congress. The Public Prosecution said drug-control policy should combine demand reduction, treatment and supply enforcement.

"prevention, awareness, and treatment with supply reduction and law enforcement"
— Emirates News Agency report on UAE Public Prosecution remarks, 28 September 2026

For healthcare operators, the practical point is coordination. A controlled-medicine case can involve a prescriber, pharmacy, insurer, regulator and prosecutor. In Dubai, the relevant health regulator is the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain, it is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, it is the Ministry of Health and Prevention (MOHAP).

What clinics and pharmacies should check

DHA already runs a Drug Control function that covers medication governance and the national platform for controlled medications. DHA’s public Drug Control page links private facilities and licensed professionals to drug-control processes, forms and platform requirements.

The operational exposure is narrow but material. Clinics that prescribe controlled medicines need current prescribing privileges, valid clinical documentation and pharmacy handover controls. Pharmacies need dispensing records that match the prescription and the regulator’s platform requirements. Insurers need claims rules that distinguish routine medicines from restricted categories before reimbursement is approved.

• Dubai: check DHA Drug Control requirements and Sheryan circulars for controlled and semi-controlled medication workflows.
• Abu Dhabi and Al Ain: align prescribing, dispensing and insurance workflows with DOH facility licensing and audit expectations.
• Northern emirates: use MOHAP rules for licensed facilities, pharmacists and controlled-medicine import or dispensing approvals.
• Travellers and patients: controlled medicines may need supporting documents and, in some cases, MOHAP approval before entry to the UAE.

The UAE Government portal states that narcotic, psychotropic and other controlled medicines of class A or B are not freely available in the UAE and cannot be freely imported. It also says these medicines must be prescribed on the official psychotropic prescription form. Patients bringing controlled medicines into the country should check the UAE Government controlled medicines page before travel.

Cost and claims implications

There is no single retail price range that applies to all controlled medicines. Prices depend on the registered product, dosage, pack size, dispensing rules and insurance network. Operators should verify prices through official medicine-price files or payer portals, then confirm coverage rules with insurers such as Daman, Thiqa and Sukoon where those networks apply to the patient.

MOHAP’s services guide gives one concrete institutional cost marker: an application fee of AED 100 for importing narcotic drugs, plus fees of 1% of invoice value with a minimum of AED 200 for each permit. That figure is a procurement and compliance reference for hospitals and pharmacies, not a patient retail price.

The next risk is auditability. COOs should test whether a controlled-medicine prescription can be traced from consultation to claim submission within one working day. CFOs should review whether rejected claims for controlled medicines are coded separately from ordinary pharmacy denials. CIOs should confirm that pharmacy systems can store the prescription, dispensing event, prescriber ID and payer approval without manual re-entry.

Patients will feel the effect at the pharmacy counter. A medicine available in another market may need a UAE-licensed prescription, a local dispensing pathway or a pre-travel permit. Clinics should give written instructions before prescribing controlled medicines to residents who travel frequently.

For provider discovery, readers can use the UAE Open Healthcare Directory to find licensed pharmacy providers across Dubai, Abu Dhabi, Sharjah, Ajman, Al Ain, Ras Al Khaimah, Fujairah and Umm Al Quwain.